ÇHeckpoint inhibitors like Keytruda and Opdivo can be incredibly powerful cancer-killing drugs – when they work, that is, less than 70% of the time. For years, scientists had hoped to find a way to identify a combination of therapies that could help these drugs work for more people.
New results from clinical tests published Thursday in Science provide some of the strongest evidence for an unusual but promising mashup: the pairing of immunotherapy drugs with fecal microbiota transplants, or FMTs.
Unlock this article by subscribing to STAT + and enjoy your first 30 days for free!
START
What is it?
STAT + is STAT’s premium subscription service for coverage and in-depth analysis of biotechnology, pharmaceutical industry, politics and life sciences. Our award-winning team covers news on Wall Street, policy developments in Washington, early scientific discoveries and results of clinical trials and health interruptions in Silicon Valley and beyond.
What’s included?
- Daily reports and analysis
- The most comprehensive coverage in the industry by a powerful team of reporters
- Subscriber-only newsletters
- Daily newsletters to inform you of the most important industry news of the day
- STAT + conversations
- Weekly opportunities to interact with our reporters and industry-leading experts in live video chats
- Exclusive industry events
- Premium access to network events only for subscribers across the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the healthcare industry
- And much more
- Exclusive interviews with industry leaders, profiles and premium tools, such as our CRISPR Trackr.